

Active substances set

Search phrase: nab-paclitaxel

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant pancreatic cancer

Nab-paclitaxel

Nab-Paclitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.



**FULL
REIMBURSEMENT**



ESMO

Tracheal, bronchus, and lung cancer

Nab-paclitaxel

Nab-Paclitaxel in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.



**REIMBURSEMENT
WITH RESTRICTIONS**



ESMO